Can blood filtering or a cancer drug save kidneys in myeloma patients?

NCT ID NCT06483139

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study looks at two treatments—plasma exchange (a blood-filtering procedure) and the drug daratumumab—to see if they help patients with multiple myeloma recover from acute kidney injury caused by light chain cast nephropathy. Researchers will track 450 adults to see who survives with better kidney function within 90 days. The goal is to find which approach works best for this serious complication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Daratumumab (a drug) and plasma exchange (a procedure that filters the blood)
What this could lead to
If successful, this could show that plasma exchange or daratumumab helps more patients recover kidney function after myeloma-related kidney injury.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove cause and effect. Kidney recovery depends on many factors, and benefits may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.